Catheter-Related Bloodstream Infections (CRBSIs)- Epidemiology Forecast-2028
SKU ID : DEL-14679808 | Publishing Date : 01-Sep-2019 | No. of pages : 100
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017–2028
Catheter-Related Bloodstream Infections (CRBSIs) - Disease Understanding
CRBSI refers to bloodstream infection attributed to an intravascular catheter by quantitative culture of the catheter tip or by differences in growth between catheter and peripheral venipuncture blood culture specimens. It is also known as catheter-related sepsis.
In the current scenario, there is no US Food and Drug Administration (FDA) approved drugs/lock solution present in the market, specifically for this indication, and therefore, the availability of new therapies will be the major market driver for the therapeutic market of CRBSI. Only one emerging therapy is present, which is in pipeline, i.e. Mino-Lok Therapy by Citius Pharmaceuticals. Due to non-competitiveness and poor pipeline, the launch of Mino-lok in the US or EU will create a huge hype and will have the only candidate in the CRBSI therapeutic landscape. The treatment of CRBSI is mainly preventive and is done by using off-label antibiotics. So, the need for a potential drug candidate is necessary and urgent.
Catheter-Related Bloodstream Infections (CRBSIs) – Epidemiology
The CRBSI epidemiology division provides insights about historical and current patient pool and forecasted trends for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population of CRBSI in the 7MM, Total Diagnosed Incident Population of CRBSI in the 7MM, and Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM] scenario of CRBSI in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017–2028.
As per ’s analysis, total Incident Population of Catheter-Related Bloodstream Infection (CRBSI in the 7MM was found to be 667,753 in 2017 and expected to increase during the forecast period of 2017-2028. The estimates show the incidence was higher in the United States and among the European 5 countries, Germany had the highest incident population of CRBSI followed by France and United Kingdom. On the other hand, Spain had the lowest incident population of CRBSI.
Another estimate of ’s analysis shows that most of the incident cases of CRBSI are confirmed with specific bacterial species. The estimates show that Gram-positive bacteria are implicated in the majority of the cases of CRBSI in comparison with Gram-negative bacteria.
• The report covers detailed overview of Catheter-related Bloodstream Infections explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of Catheter-related Bloodstream Infections
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by type specific cases and severity specific cases of Catheter-related Bloodstream Infections in the 7MM
Catheter-related Bloodstream Infections Report Key Strengths
• 10 Year Forecast of Catheter-related Bloodstream Infections epidemiology
• 7MM Coverage
• Total Incident Population of CRBSI
• Total Diagnosed Incident Population of CRBSI
• Diagnosed Incidence of CRBSI by Causative Pathogens
Catheter-related Bloodstream Infections Report Assessment
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population